Luis Hidalgo, PhD, D(ABHI)
- Histocompatibility Lab Director
- Division of Transplantation
448 Science Drive
Madison WI 53711
- PhD, Immunology, University of Alberta, 2005
- Diplomate - American Board of Histocompatibility and Immunogenetics, 2012
The focus of my research laboratory aims at elucidating the various mechanisms used by the human immune system to damage transplanted organs with specific focus on antibody-mediated rejection (ABMR). The immunologic understanding of ABMR that we have thus far identified points to a limited number of players. These players include donor-specific antibodies (DSA) (primarily targeting HLA), endothelial cell targets, and NK cell and monocyte effector cells working in concert to maximize their damage.
The laboratory’s projects are therefore split into two principal areas: immune effector cells in ABMR, and endothelial cell biology. The immune effector projects have a strong focus on assessing immune function of NK cells and monocytes particularly as it relates to activation through their Fc-gamma receptors. Endothelial cell studies relate to endothelial susceptibility to immune damage in ABMR and regulation of HLA surface expression. Findings within either of these areas have clinical implications as all of our studies are based on human immunology using primary cells. Our ultimate goal is to identify donor and recipient characteristics that define immunologic risk beyond the limited characteristics currently used.
Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes.
Halloran PF, Madill-Thomsen KS, Pon S, Sikosana MLN, Böhmig GA, Bromberg J, Einecke G, Eskandary F, Gupta G, Hidalgo LG, Myslak M, Viklicky O, Perkowska-Ptasinska A, INTERCOMEX Investigators
Am J Transplant 2022 May 16;
[PubMed ID: 35575435]
Factors affecting sensitization following kidney allograft failure.
Garg N, Viney K, Burger J, Hidalgo L, Parajuli S, Aziz F, Mohamed MA, Djamali A, Mandelbrot DA
Clin Transplant 2022 03; 36(3): e14558
[PubMed ID: 34923658]
Impact of low-level pretransplant donor-specific antibodies on outcomes after kidney transplantation.
Parajuli S, Bath NM, Hidalgo L, Leverson G, Garg N, R Redfield R, Mandelbrot DA
Immun Inflamm Dis 2021 12; 9(4): 1508-1519
[PubMed ID: 34407300]
Donor-Specific Antibody Is Associated with Increased Expression of Rejection Transcripts in Renal Transplant Biopsies Classified as No Rejection.
Madill-Thomsen KS, Böhmig GA, Bromberg J, Einecke G, Eskandary F, Gupta G, Hidalgo LG, Myslak M, Viklicky O, Perkowska-Ptasinska A, Halloran PF, INTERCOMEX Investigators
J Am Soc Nephrol 2021 11; 32(11): 2743-2758
[PubMed ID: 34253587]
Modest Improvements in Refractory Antibody-Mediated Rejection After Prolonged Treatment.
Degner KR, Parajuli S, Aziz F, Garg N, Mohamed M, Mandelbrot DA, Panzer SE, Wilson NA, Reese SR, Van Hyfte K, Zhong W, Hidalgo LG, Nickerson P, Djamali A
Kidney Int Rep 2021 May; 6(5): 1397-1401
[PubMed ID: 34013117]